Kamada/$KMDA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kamada
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Ticker
$KMDA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Rehovot, Israel
Employees
420
ISIN
IL0010941198
Website
Kamada Metrics
BasicAdvanced
$420M
25.72
$0.28
0.15
$0.20
5.54%
Price and volume
Market cap
$420M
Beta
0.15
52-week high
$9.16
52-week low
$4.74
Average daily volume
81K
Dividend rate
$0.20
Financial strength
Current ratio
3.304
Quick ratio
1.931
Long term debt to equity
3.698
Total debt to equity
4.405
Interest coverage (TTM)
34.35%
Profitability
EBITDA (TTM)
36.497
Gross margin (TTM)
44.23%
Net profit margin (TTM)
9.60%
Operating margin (TTM)
14.24%
Effective tax rate (TTM)
8.26%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
4.14%
Return on equity (TTM)
6.44%
Valuation
Price to earnings (TTM)
25.723
Price to revenue (TTM)
2.455
Price to book
5.72
Price to tangible book (TTM)
11.99
Price to free cash flow (TTM)
11.237
Free cash flow yield (TTM)
8.90%
Free cash flow per share (TTM)
64.25%
Dividend yield (TTM)
2.77%
Forward dividend yield
5.54%
Growth
Revenue change (TTM)
11.83%
Earnings per share change (TTM)
31.21%
3-year revenue growth (CAGR)
16.11%
10-year revenue growth (CAGR)
9.61%
3-year earnings per share growth (CAGR)
23.17%
10-year earnings per share growth (CAGR)
-4.17%
What the Analysts think about Kamada
Analyst ratings (Buy, Hold, Sell) for Kamada stock.
Bulls say / Bears say
Kamada anticipates continued double-digit growth in 2025, projecting revenues between $178 million and $182 million, driven by its six FDA-approved plasma-derived therapies and the expansion of biosimilar launches in Israel. (benzinga.com)
The company is expanding its plasma collection operations, with a new facility in San Antonio, Texas, expected to contribute $8 million to $10 million annually once fully operational. (benzinga.com)
Kamada's inhaled alpha-1 antitrypsin (AAT) therapy, targeting a market exceeding $2 billion, is progressing through a Phase 3 trial, representing a significant commercial opportunity if approved. (benzinga.com)
Kamada's stock rating was downgraded by StockNews.com from 'strong-buy' to 'buy' in March 2025, indicating potential concerns about future performance. (americanbankingnews.com)
The company reported adjusted earnings of 7 cents per share for Q4 2024, down from 9 cents in the same quarter the previous year, suggesting a decline in profitability. (tradingview.com)
Short interest in Kamada's stock increased by 61.8% in March 2025, indicating growing bearish sentiment among investors. (techdows.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
Kamada Financial Performance
Revenues and expenses
Kamada Earnings Performance
Company profitability
Kamada News
AllArticlesVideos
Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East
GlobeNewsWire·3 days ago
Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kamada stock?
Kamada (KMDA) has a market cap of $420M as of June 20, 2025.
What is the P/E ratio for Kamada stock?
The price to earnings (P/E) ratio for Kamada (KMDA) stock is 25.72 as of June 20, 2025.
Does Kamada stock pay dividends?
Yes, the Kamada (KMDA) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $0.2 and the yield is 5.54%. Kamada has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Kamada dividend payment date?
The next Kamada (KMDA) dividend payment date is unconfirmed.
What is the beta indicator for Kamada?
Kamada (KMDA) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.